MAPT and Alzheimer disease: It has been shown in our previous study that selenomethionine (Se-Met), a major form of Se in organisms, effectively increase oxidation resistance as well as reduce the production and deposition of Aβ and tau hyperphosphorylation in the cortex and hippocampus of a triple transgenic mouse model of AD (3× Tg-AD), thereby suggesting a promising therapeutic option for AD [17].